You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Multiplexing Cancer Sample Preparation: Indirect Immunomagnetic Enrichment

    SBC: ADVANCED LIQUID LOGIC            Topic: N/A

    DESCRIPTION (provided by applicant): Biomarkers of clinical activity are critical for targeted anti-cancer therapy development and are becoming important for the care of individual patients. In a prototypical tyrosine kinase pathway, governed by the epider mal growth factor receptor (EGFR), functional activity of the pathway is assessed by the phosphorylation status of EGFR and downstream signalin ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  2. Improved Silicon Drift Detector Coincidence Rejection for Digital Pulse Processors

    SBC: 4pi Analysis, Inc.            Topic: N/A

    The recent emergence of the Silicon Drift detector (SDD), for use in Energy Dispersive x-ray Spectroscopy (EDS), has made possible x-ray event streams with input count rates in the range of 1-10 Mcps. Modern digital pulse processors are therefore required to run at fast time constants to achieve reasonable throughput; however, this causes significant coincidence artifacts to appear in the spectrum ...

    SBIR Phase I 2008 Department of CommerceNational Institute of Standards and Technology
  3. Localized Growth Factor Therapy for Surgical Hernia Repair

    SBC: AFFINERGY, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Over 700,000 surgical hernia repairs are performed each year in the United States and despite recent advances, a significant rate of recurrence persists. The incorporation of biocompatable mesh to strengthen the abdomi nal fascia has largely replaced high-tension suturing techniques in hernia repair. Currently, the preferred biomaterials include durable synthe ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  4. Antibiotic-binding Peptides for Biofilm Prevention on Ventriculoperitoneal Shunts

    SBC: AFFINERGY, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Ventriculoperitoneal (VP) shunts are used to treat pediatric and neonatal hydrocephalus in severe cases, representing approximately 1/3rd of affected infants. Due to the high susceptibility for infection and mechanica l breakdown, the failure rate of VP shunts is around 30-40%. A need therefore exists to improve infection prevention for this procedure, likely ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  5. Tissue-targeted Antibiotics for the Prevention of Surgical Site Infection

    SBC: AFFINERGY, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): The Centers for Disease Control estimates that as many as 2 million people contract infections in hospitals each year, with as many as 100,000 deaths. Approximately 1/4 of hospital related infections (~500,000) are surg ical site infections. For each single patient, surgical site infections have been reported to require a median 6.5 additional days of hospital ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  6. Self Assembling High Affinity Peptides for Point of Care Drug-Device Combinations

    SBC: AFFINERGY, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Infection surrounding metal implants is a common and sometimes devastating cause of implant failure in a number of fields including oral, craniomaxillofacial (CMF), orthopedic, and cardiovascular surgery. These infectio ns, which arise from the establishment of biofilms on device surfaces, not only necessitate new surgeries but in themselves present a significa ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  7. Prohealing Coatings for Cardiovascular Implants

    SBC: AFFINERGY, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Summary Improving cardiovascular implants to reduce thrombosis and other confounds has been a long-term goal of medical science. Grafts and endovascular stents have been recently modified to include new materials, atta ched cells or drug-eluting polymers to make them more biocompatible. While these efforts represent substantial progress, the progression from i ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  8. Printed Disposable Sensor for Quantitative HIV RNA Measurement of Viral Load

    SBC: ALDERON BIOSCIENCES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The National Institutes of Allergy and Infectious Disease have called for better tools for the detection and diagnosis of emerging and re-emerging infectious diseases. In response to this need, Alderon Biosciences propo ses research to develop printed disposable sensors for quantification of HIV RNA in resource-poor settings. Our research is important for devel ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  9. Pseudo Target Amplification Diagnostics

    SBC: ALDERON BIOSCIENCES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The National Institute of Allergy and Infectious Disease has called for better tools for the detection and diagnosis of emerging and re-emerging infectious diseases such as influenza. The need is for tests that are prac tical and affordable for use at point-of-care and near point-of-care settings, such as local public health departments, underdeveloped countrie ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  10. Preclinical Development of AAV-Galanin for Epilepsy

    SBC: ASKLEPIOS BIOPHARMACEUTICAL, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): This proposal seeks to leverage proprietary technical advances in Adeno-Associated Virus (AAV) vector mediated gene therapy to develop an AAV based Galanin gene delivery for the treatment of epilepsy. Asklepios Biopharm aceutical, Inc. (Askbio) has obtained intellectual property rights to develop and commercialize an anti-epileptic biologic containing three key ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government